Trial intelligence / Profile preview

PRO-DART propranolol dose-finding study for reactive aggression

2026-526545-95-00Phase 2Authorised

Sponsor
Radboud University Medical Center
Start
Sep 2026
Modality
Small Molecules
Countries
1
01

Overview

Phase 2 trial of propranolol, sponsored by Radboud University Medical Center. Primary endpoint: Aggressivity during provocative virtual reality scenarios. Planned start Sep 2026; status: authorised.

02

Drugs

propranolol

Beyond the preview

Go deeper on 2026-526545-95-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2026-526545-95-00.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call